Codexis, Inc. (CDXS) Given Consensus Recommendation of “Hold” by Brokerages
Codexis, Inc. (NASDAQ:CDXS) has earned an average recommendation of “Hold” from the seven analysts that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $6.80.
Several equities analysts have recently commented on CDXS shares. HC Wainwright set a $8.00 target price on shares of Codexis and gave the company a “buy” rating in a research report on Friday. Zacks Investment Research cut shares of Codexis from a “hold” rating to a “sell” rating in a research report on Tuesday, May 23rd. Jefferies Group LLC started coverage on shares of Codexis in a research report on Wednesday, May 31st. They issued a “buy” rating and a $8.00 target price for the company. BidaskClub upgraded shares of Codexis from a “hold” rating to a “buy” rating in a research report on Sunday, July 16th. Finally, ValuEngine cut shares of Codexis from a “hold” rating to a “sell” rating in a research report on Thursday, July 6th.
Shares of Codexis (CDXS) opened at 5.25 on Friday. Codexis has a 52 week low of $3.60 and a 52 week high of $5.70. The firm’s 50-day moving average is $5.35 and its 200 day moving average is $4.72. The company’s market capitalization is $216.59 million.
Codexis (NASDAQ:CDXS) last issued its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.13) EPS for the quarter, meeting the consensus estimate of ($0.13). The company had revenue of $10.30 million during the quarter, compared to analysts’ expectations of $9.61 million. Codexis had a negative net margin of 40.70% and a negative return on equity of 98.28%. The business’s revenue for the quarter was down 35.6% compared to the same quarter last year. During the same period in the previous year, the company earned $0.12 EPS. On average, analysts anticipate that Codexis will post ($0.32) earnings per share for the current fiscal year.
Institutional investors have recently added to or reduced their stakes in the company. Nationwide Fund Advisors boosted its position in Codexis by 15.7% in the second quarter. Nationwide Fund Advisors now owns 21,568 shares of the biotechnology company’s stock worth $118,000 after buying an additional 2,928 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in Codexis by 7,242.9% in the first quarter. Tower Research Capital LLC TRC now owns 22,249 shares of the biotechnology company’s stock worth $107,000 after buying an additional 21,946 shares in the last quarter. Bank of America Corp DE boosted its position in Codexis by 2.9% in the first quarter. Bank of America Corp DE now owns 25,477 shares of the biotechnology company’s stock worth $122,000 after buying an additional 717 shares in the last quarter. Perkins Capital Management Inc. bought a new position in Codexis during the second quarter worth about $164,000. Finally, Rhumbline Advisers boosted its position in Codexis by 23.3% in the second quarter. Rhumbline Advisers now owns 42,872 shares of the biotechnology company’s stock worth $234,000 after buying an additional 8,095 shares in the last quarter. Institutional investors and hedge funds own 54.90% of the company’s stock.
Codexis Company Profile
Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.
Receive News & Ratings for Codexis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.